COVID-19 Skin Symptoms: Rashes, COVID Toes, and More

You've been told your skin symptoms are unrelated to your recent COVID-19 infection. But the red, itchy patches on your torso appeared days after your fever broke, and the purple discoloration on your toes showed up when you were otherwise feeling fine. Skin manifestations of COVID-19 are real, documented, and more common than early pandemic reports suggested.

Key Takeaways

• COVID-19 can trigger multiple distinct skin patterns, not just respiratory symptoms.
• What are COVID toes? Chilblain-like lesions appearing as red or purple discoloration on toes.
• Skin rashes occur in up to 20% of confirmed COVID-19 cases.
• Most COVID-related skin findings appear during active infection or shortly after recovery.
• COVID itchy skin often presents as urticarial or maculopapular eruptions.
• Vascular changes drive many COVID skin symptoms, not just surface inflammation.
• Skin manifestations can occur without respiratory symptoms in some patients.

What COVID-19 Does to Skin at the Cellular Level

COVID-19 is primarily a respiratory virus, but SARS-CoV-2 doesn't limit itself to the lungs. The virus binds to ACE2 receptors, which are abundant not only in respiratory epithelium but also in vascular endothelial cells throughout the body, including those lining blood vessels in the skin. When the virus triggers an immune response, that response doesn't stay localized. Cytokines, interferons, and immune cells circulate systemically, and skin becomes a visible site where that immune activation plays out.

The skin manifestations of COVID-19 fall into several mechanistically distinct categories:

1. Direct viral effects on blood vessels causing endothelial damage
2. Immune-mediated inflammation triggered by circulating cytokines and immune complexes
3. Hypercoagulability and microthrombotic events leading to vascular occlusion
4. Type I interferon responses causing localized tissue inflammation

The clinical presentation depends on which pathway dominates, the timing of the immune response, and individual variation in vascular reactivity and immune tone.

The Five Main Patterns of COVID-19 Skin Involvement

Maculopapular rashes

Maculopapular rashes present as flat or slightly raised red patches, often on the trunk and limbs. They resemble viral exanthems seen with other infections and typically appear during the acute phase of illness. The mechanism involves T-cell mediated inflammation in response to viral antigens or circulating immune complexes. These rashes are usually self-limited, resolving within days to weeks as the acute infection clears.

Urticarial eruptions

COVID itchy skin frequently manifests as urticaria, or hives. These raised, red, intensely itchy welts can appear suddenly and migrate across the body. Urticarial lesions in COVID-19 are thought to result from mast cell activation triggered by viral antigens or immune complexes binding to IgE receptors. Histamine release causes the characteristic wheal-and-flare response. Unlike chronic urticaria, COVID-associated hives typically resolve once the immune system clears the viral trigger, though they can persist for several weeks in some cases.

Vesicular lesions

Small fluid-filled blisters resembling chickenpox have been documented in COVID-19 patients, particularly early in the pandemic. These vesicles contain serous fluid and can appear on the trunk, limbs, or face. The pathophysiology likely involves direct viral cytopathic effects on keratinocytes or localized immune-mediated damage to the epidermis. Vesicular eruptions tend to appear early in the disease course and may precede respiratory symptoms.

Chilblain-like lesions (COVID toes)

What are COVID toes? These distinctive lesions appear as red or purple discoloration on the toes and sometimes fingers, often with swelling and tenderness. The mechanism involves a combination of microvascular inflammation, endothelial dysfunction, and microthrombi formation in small vessels of the digits. Type I interferon responses appear to play a central role, with elevated interferon levels correlating with the presence of these lesions. Unlike traditional chilblains triggered by cold exposure, COVID toes can appear in warm weather and persist for weeks to months.

Livedoid and petechial patterns

These vascular patterns reflect more severe endothelial involvement. Livedo reticularis appears as a mottled, net-like purple discoloration, typically on the legs. Petechiae are pinpoint red or purple spots caused by capillary bleeding. Both patterns suggest microvascular injury and thrombosis. In severe COVID-19, a hypercoagulable state driven by endothelial activation, complement activation, and elevated D-dimer levels can lead to widespread microthrombotic events. When these occur in dermal vessels, the result is visible purpura, petechiae, or even necrotic skin lesions in extreme cases.

How Systemic Inflammation Reaches the Skin

COVID-19 skin symptoms aren't isolated dermatologic events. They're visible manifestations of systemic processes. The cytokine storm that characterizes severe COVID-19 involves massive release of interleukin-6, interleukin-1, tumor necrosis factor-alpha, and other inflammatory mediators. These cytokines don't discriminate by organ. They circulate throughout the body, activating endothelial cells, recruiting immune cells, and triggering inflammation wherever blood vessels exist, including the extensive vascular network of the skin.

The complement system also plays a role. COVID-19 activates both the classical and alternative complement pathways, leading to deposition of complement components in blood vessel walls. In skin biopsies from patients with COVID-related purpura and necrosis, complement deposition has been documented alongside microvascular thrombosis.

The timing of skin manifestations relative to other COVID-19 symptoms provides clues about mechanism:

• Urticarial and maculopapular rashes tend to appear during the acute inflammatory phase when viral load and cytokine levels peak.
• COVID toes often emerge later in the disease course or after respiratory symptoms have resolved, suggesting a delayed immune response rather than active viral replication.
• Vesicular eruptions typically appear early and may precede other symptoms.
• Petechial and purpuric patterns correlate with peak hypercoagulability in severe disease.

Why Some People Develop Skin Symptoms and Others Don't

Not everyone infected with SARS-CoV-2 develops skin manifestations. The reasons for this variation involve genetics, immune phenotype, and viral factors. Individuals with robust type I interferon responses appear more likely to develop chilblain-like lesions. Those with a tendency toward mast cell activation or atopic conditions may be predisposed to urticarial eruptions. Genetic variants affecting endothelial function, coagulation pathways, or complement regulation could influence who develops vascular skin patterns.

Age also matters. COVID toes disproportionately affect younger patients, often children and adolescents with mild or asymptomatic infection. This age distribution suggests that a vigorous, perhaps overactive, immune response in younger individuals drives these lesions. Older adults, who tend to have more severe respiratory disease, are more likely to develop petechial or purpuric patterns associated with coagulopathy and critical illness. Viral load and strain may also play a role, with early pandemic reports documenting higher rates of certain skin findings that decreased as different SARS-CoV-2 variants emerged.

When Skin Symptoms Signal Systemic Complications

Most COVID-19 skin manifestations are benign and self-limited. But certain patterns warrant closer attention. Petechiae, purpura, and necrotic lesions suggest significant coagulopathy or vasculitis. These findings are more common in hospitalized patients with severe disease and correlate with elevated inflammatory markers, D-dimer, and risk of thrombotic complications. Patients presenting with these vascular patterns should be evaluated for systemic hypercoagulability, which may require anticoagulation.

Persistent or worsening skin lesions after acute COVID-19 has resolved can indicate post-acute sequelae of SARS-CoV-2 infection, commonly known as long COVID. Some patients report ongoing urticaria, hair loss, or persistent chilblain-like lesions months after initial infection. The mechanisms behind these prolonged symptoms are still being investigated but may involve persistent immune dysregulation, autoantibody formation, or viral persistence in tissues. Skin symptoms appearing in the absence of respiratory findings can also be clinically significant, as they may represent the only manifestation of COVID-19 in some individuals, particularly children.

What Biomarkers Reveal About COVID-19 Skin Involvement

When skin symptoms persist or occur alongside systemic symptoms, laboratory testing can clarify the underlying drivers. Elevated high-sensitivity C-reactive protein and erythrocyte sedimentation rate reflect systemic inflammation. D-dimer elevation suggests hypercoagulability and increased thrombotic risk, particularly relevant in patients with purpuric or necrotic skin lesions. Complete blood counts may reveal lymphopenia, a common finding in COVID-19 that correlates with disease severity.

Autoantibody testing can be informative in cases of persistent or atypical skin findings:

• Antiphospholipid antibodies increase thrombotic risk and can cause livedo reticularis or skin necrosis.
• Antinuclear antibodies and other autoimmune markers may emerge in post-acute COVID, particularly in patients with ongoing inflammatory symptoms.
• Tracking these markers over time helps distinguish transient immune activation from emerging autoimmune disease.

For patients with suspected vascular involvement, assessing endothelial function and coagulation status is critical. Markers like von Willebrand factor, fibrinogen, and platelet counts provide insight into the degree of endothelial activation and coagulopathy. In severe cases, complement levels (C3, C4) may be depressed due to consumption, indicating active complement-mediated vascular injury.

Connecting Skin Findings to Broader Health Patterns

COVID-19 skin symptoms aren't just about the skin. They're windows into systemic immune and vascular health. If you've experienced persistent or severe dermatologic manifestations during or after COVID-19, Superpower's 100+ biomarker panel can help identify the underlying drivers. Measuring inflammatory markers, coagulation factors, immune cell counts, and autoantibodies provides a broader picture of how your body responded to infection and whether lingering immune dysregulation is affecting your recovery. Understanding these patterns allows you to address not just the visible symptoms but the systemic processes driving them.